The long-term objective of this project is to develop a commercial product for the topical treatment of acne and skin diseases. the specific aim of the proposal is to invent a prodrug that can be used effectively and safely for the topical treatment of acne. since isotretinoin (13-cis-retinoic acid,… More

Psoriasis is a disease that affects millions of americans with chronic recurrent exacerbations and remissions that areemotionally and physically debilitating. several treatmentsare available, but in many cases these are inadequate. this application is based on the premise that topical administration… More

The goal of this project is to develop a synthetic inhibitor of elastase that will be effective and safe in the treatment of emphysema. two different laboratories reported that chloromethyl ketone (cmk) is effective in animal models of emphysema. however, the cmk are too toxic for human use. we have… More

In the United States alone, approximately 450,000 people yearly suffer a cardiac arrest outsidethe hospital. Less than 10% of these patients are discharged from the hospital alive, and of these,approximately 60% suffer some form of permanent neurologic injury. The poor resuscitation rates… More

DESCRIPTION: (Applicant's description) Combinatorial methods for the synthesis of new drug substances require high throughput techniques for evaluation of structure-activity relationships. Microliter plates with immobilized target receptors can rapidly reduce thousands of… More

DESCRIPTION (provided by applicant): Molecular Design International, Inc. (MDI) has designed and synthesized three synthetic retinoids based on the removal of the free carboxylic acid proton and replacement with an ester moiety in 14-all trans retinoic acid (RA), 13-cis retinoic acid (13-cis RA)… More

DESCRIPTION (provided by applicant): This application represents the Phase II version of SBIR grant R43 AR049621 entitled "Non-Irritating Retinoids for the Treatment of Aging Skin". Studies carried out prior to Phase I and during the Phase I portion of this project have demonstrated that a synthetic… More

DESCRIPTION (provided by applicant): MDI 301 is a synthetic retinoid that is similar to all-trans retinoic acid (RA) in its ability to stimulate collagen synthesis and inhibit the major collagen-degrading enzymes in skin. A major feature that distinguishes MDI 301 from RA is its lack of irritation… More

DESCRIPTION (provided by applicant): MDI 301 is a synthetic retinoid that is similar to all-trans retinoic acid (RA) in its ability to stimulate collagen synthesis and inhibit the major collagen-degrading enzymes in skin. A feature that distinguishes MDI 301 from RA is its lack of irritation when… More

DESCRIPTION (provided by applicant): MDI-301 is a synthetic retinoid. MDI-301, like RA, induces collagen synthesis and reduces expression of collagen-degrading matrix metalloproteinases in the skin. This agent also induces epidermal thickening. However, un like RA, MDI-301 is non-irritating when… More

DESCRIPTION (provided by applicant): The overall goal of our work is to establish the potency and efficacy of a novel 2-adrenergic receptor agonist (compound 49b) in the prevention and/or reversal of non-proliferative diabetic retinopathy. Diabetic retinopathy is the leading cause of blindness… More